These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 19245367)

  • 1. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Caboni P; Garau A; Carboni E; Carta AR
    Eur J Neurosci; 2009 Mar; 29(5):954-63. PubMed ID: 19245367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosiglitazone decreases peroxisome proliferator receptor-γ levels in microglia and inhibits TNF-α production: new evidences on neuroprotection in a progressive Parkinson's disease model.
    Carta AR; Frau L; Pisanu A; Wardas J; Spiga S; Carboni E
    Neuroscience; 2011 Oct; 194():250-61. PubMed ID: 21839812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
    Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
    Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.
    Schintu N; Frau L; Ibba M; Garau A; Carboni E; Carta AR
    Neurotox Res; 2009 Aug; 16(2):127-39. PubMed ID: 19526289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease.
    Frau L; Borsini F; Wardas J; Khairnar AS; Schintu N; Morelli M
    Synapse; 2011 Mar; 65(3):181-8. PubMed ID: 20665698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences on MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in C57BL/6 mice.
    Ookubo M; Yokoyama H; Kato H; Araki T
    Mol Cell Endocrinol; 2009 Nov; 311(1-2):62-8. PubMed ID: 19631714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.
    Luo Y; Yin W; Signore AP; Zhang F; Hong Z; Wang S; Graham SH; Chen J
    J Neurochem; 2006 Apr; 97(2):435-48. PubMed ID: 16539667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.
    Rojo AI; Innamorato NG; Martín-Moreno AM; De Ceballos ML; Yamamoto M; Cuadrado A
    Glia; 2010 Apr; 58(5):588-98. PubMed ID: 19908287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
    Kreisler A; Gelé P; Wiart JF; Lhermitte M; Destée A; Bordet R
    Brain Res; 2007 Mar; 1135(1):77-84. PubMed ID: 17196944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen down-regulates glial activation in male mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication.
    Tripanichkul W; Sripanichkulchai K; Finkelstein DI
    Brain Res; 2006 Apr; 1084(1):28-37. PubMed ID: 16564034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The acute and the long-term effects of nigral lipopolysaccharide administration on dopaminergic dysfunction and glial cell activation.
    Iravani MM; Leung CC; Sadeghian M; Haddon CO; Rose S; Jenner P
    Eur J Neurosci; 2005 Jul; 22(2):317-30. PubMed ID: 16045485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in mice.
    Shepherd KR; Lee ES; Schmued L; Jiao Y; Ali SF; Oriaku ET; Lamango NS; Soliman KF; Charlton CG
    Pharmacol Biochem Behav; 2006 Mar; 83(3):349-59. PubMed ID: 16580056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of inclusion body formation in the MPTP mouse model of Parkinson's disease.
    Shimoji M; Zhang L; Mandir AS; Dawson VL; Dawson TM
    Brain Res Mol Brain Res; 2005 Mar; 134(1):103-8. PubMed ID: 15790534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain.
    Domenger D; Dea D; Theroux L; Moquin L; Gratton A; Poirier J
    Exp Neurol; 2012 Jan; 233(1):513-22. PubMed ID: 22155743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of manganese exposure on MPTP neurotoxicities.
    Baek SY; Lee MJ; Jung HS; Kim HJ; Lee CR; Yoo C; Lee JH; Lee H; Yoon CS; Kim YH; Park J; Kim JW; Jeon BS; Kim Y
    Neurotoxicology; 2003 Aug; 24(4-5):657-65. PubMed ID: 12900079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.
    Knyihár-Csillik E; Csillik B; Pákáski M; Krisztin-Péva B; Dobó E; Okuno E; Vécsei L
    Neuroscience; 2004; 126(4):899-914. PubMed ID: 15207325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of angiotensin-converting enzyme inhibitor perindopril on interneurons in MPTP-treated mice.
    Kurosaki R; Muramatsu Y; Kato H; Watanabe Y; Imai Y; Itoyama Y; Araki T
    Eur Neuropsychopharmacol; 2005 Jan; 15(1):57-67. PubMed ID: 15572274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.